Changes in clinical markers observed from pharmacist-managed cardiovascular risk reduction clinics in federally qualified health centers: A retrospective cohort study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
03
2021
accepted:
21
02
2023
entrez:
15
3
2023
pubmed:
16
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Reductions in hemoglobin A1c (HbA1C) have been associated with improved cardiovascular outcomes and savings in medical expenditures. One public health approach has involved pharmacists within primary care settings. The objective was to assess change in HbA1C from baseline after 3-5 months of follow up in pharmacist-managed cardiovascular risk reduction (CVRR) clinics. This retrospective cohort chart review occurred in eight pharmacist-managed CVRR federally qualified health clinics (FQHC) in Indiana, United States. Data were collected from patients seen by a CVRR pharmacist within the timeframe of January 1, 2015 through February 28, 2020. Data collected include: demographic characteristics and clinical markers between baseline and follow-up. HbA1C from baseline after 3 to 5 months was assessed with pared t-tests analysis. Other clinical variables were assessed and additional analysis were performed at 6-8 months. Additional results are reported between 9 months and 36 months of follow up. The primary outcome evaluation included 445 patients. Over 36 months of evaluation, 3,803 encounters were described. Compared to baseline, HbA1C was reduced by 1.6% (95%CI -1.8, -1.4, p<0.01) after 3-5 months of CVRR care. Reductions in HbA1C persisted at 6-8 months with a reduction of 1.8% ([95%CI -2.0, -1.5] p<0.01). The follow-up losses were 29.5% at 3-5 months and 93.2% at 33-36 months. Our study augments the existing literature by demonstrating the health improvement of pharmacist-managed CVRR clinics. The great proportion of loss to follow-up is a limitation of this study to be considered. Additional studies exploring the expansion of similar models may amplify the public health impact of pharmacist-managed CVRR services in primary care sites.
Sections du résumé
BACKGROUND
Reductions in hemoglobin A1c (HbA1C) have been associated with improved cardiovascular outcomes and savings in medical expenditures. One public health approach has involved pharmacists within primary care settings. The objective was to assess change in HbA1C from baseline after 3-5 months of follow up in pharmacist-managed cardiovascular risk reduction (CVRR) clinics.
METHODS
This retrospective cohort chart review occurred in eight pharmacist-managed CVRR federally qualified health clinics (FQHC) in Indiana, United States. Data were collected from patients seen by a CVRR pharmacist within the timeframe of January 1, 2015 through February 28, 2020. Data collected include: demographic characteristics and clinical markers between baseline and follow-up. HbA1C from baseline after 3 to 5 months was assessed with pared t-tests analysis. Other clinical variables were assessed and additional analysis were performed at 6-8 months. Additional results are reported between 9 months and 36 months of follow up.
RESULTS
The primary outcome evaluation included 445 patients. Over 36 months of evaluation, 3,803 encounters were described. Compared to baseline, HbA1C was reduced by 1.6% (95%CI -1.8, -1.4, p<0.01) after 3-5 months of CVRR care. Reductions in HbA1C persisted at 6-8 months with a reduction of 1.8% ([95%CI -2.0, -1.5] p<0.01). The follow-up losses were 29.5% at 3-5 months and 93.2% at 33-36 months.
CONCLUSIONS
Our study augments the existing literature by demonstrating the health improvement of pharmacist-managed CVRR clinics. The great proportion of loss to follow-up is a limitation of this study to be considered. Additional studies exploring the expansion of similar models may amplify the public health impact of pharmacist-managed CVRR services in primary care sites.
Identifiants
pubmed: 36920963
doi: 10.1371/journal.pone.0282940
pii: PONE-D-21-08257
pmc: PMC10016666
doi:
Substances chimiques
Glycated Hemoglobin
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0282940Informations de copyright
Copyright: © 2023 Gonzalvo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Health Syst Pharm. 2019 Jun 3;76(12):874-887
pubmed: 31361855
BMC Endocr Disord. 2018 Dec 27;18(1):97
pubmed: 30591044
Am J Health Syst Pharm. 2015 May 1;72(9):745-51
pubmed: 25873622
Front Endocrinol (Lausanne). 2017 Jan 24;8:6
pubmed: 28167928
J Endocrinol Invest. 2019 Oct;42(10):1165-1169
pubmed: 30955180
J Eval Clin Pract. 2021 Apr;27(2):365-370
pubmed: 32548871
Cochrane Database Syst Rev. 2018 Sep 04;9:CD013102
pubmed: 30178872
Diabetes Educ. 2011 Nov-Dec;37(6):801-12
pubmed: 22021025
J Prim Care Community Health. 2017 Oct;8(4):324-331
pubmed: 28381095
J Manag Care Spec Pharm. 2017 Mar;23(3):318-326
pubmed: 28230459
Curr Cardiol Rev. 2015;11(3):238-45
pubmed: 25418513
JAMA Intern Med. 2016 May 1;176(5):712-4
pubmed: 27064681
Diabetes Care. 2009 Jan;32(1):187-92
pubmed: 19092168
JAMA. 2001 Jan 10;285(2):182-9
pubmed: 11176811
Prev Chronic Dis. 2019 Nov 21;16:E153
pubmed: 31753083
Curr Probl Cardiol. 2019 Sep;44(9):276-293
pubmed: 30173910